A constituent of the FTSE 100 Index, GlaxoSmithKline plc is a healthcare major with a focus on development, manufacture and commercialisation of pharmaceuticals, vaccines, and consumer healthcare products. With its base in London, the company was formed in 2000 after Glaxo Wellcome and SmithKline Beecham merged. Its main focus is to provide innovative pharmaceutical medicines, health products, and vaccines.
The company operates in two segments: Pharmaceuticals and Vaccines. The company is engaged in research across six areas: Oncology, Vaccines, Respiratory diseases, Immuno-inflammation and human immunodeficiency virus, and rare diseases. It provides and develops medicines to treat acute and chronic diseases. The company provides vaccines for people of all age groups. It offers drugs for the treatment of HIV, respiratory diseases, cancer, immuno-inflammation, viral symptoms, central nervous system (CNS) related, metabolic, cardiovascular and urogenital, anti-bacterial, dermatological and rare diseases.
The company has three business segments globally: research, development and manufacturing. The company’s objective is to provide high quality healthcare to people by discovering, developing, and manufacturing new and innovative medicines.
According to Forbes, the company was the sixth largest pharmaceutical company across the world in 2019. It is listed on London Stock Exchange and New York Stock Exchange.
GLAXOSMITHKLINE PLC C8 Gsk House, 980 Great West Road, Brentford, TW8 9GS, United Kingdom
+44 20 8047 5000